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We report a case of toxic epidermal necrolysis with ocular involvement following 
vaccination for hemorrhagic fever with renal syndrome. A healthy 20-year-old 
male soldier presented with confluent purpuric and erythematous dusky red mac-
ules evolving to flaccid blister and epidermal detachment on the whole body with 
conjunctival injection. The patient had no antecedent medical or surgical condi-
tions except for two doses of hemorrhagic fever with renal syndrome vaccination. 
With supportive care, skin lesions were improved. Ophthalmic examinations re-
vealed conjunctival injection with epithelial defects in both eyes. Ocular complica-
tions were resolved after amniotic membrane transplantation. Toxic epidermal 
necrolysis may be considered as a possible complication of hemorrhagic fever 
with renal syndrome vaccination.
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INTRODUCTION
Toxic epidermal necrolysis (TEN) is an acute and severe skin reaction character-
ized by widespread erythema, blisters, and sheet-like skin loss, often associated 
with a systemic toxic condition and mucous membrane involvement including the 
ocular tissues.1-6 TEN is assumed to be related to hypersensitivity reactions to 
drugs and infections.1-6 Vaccination has been reported as a rare triggering factor for 
erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and TEN.7-10 To 
date, there is no report of EM/SJS/TEN related to hemorrhagic fever with renal 
syndrome (HFRS) vaccination. We report herein a case of TEN with ocular in-
volvement following vaccination for HFRS.     
CASE REPORT
A healthy 20-year-old male soldier presented with confluent purpuric and ery-
thematous dusky red macules evolving to flaccid blister and epidermal detach-
ment on the whole body with extensive erosions and necroses of the oral mucosa TEN after HFRS Vaccination
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bilateral amniotic membrane transplantation (AMT) was 
performed covering whole ocular surface including cornea, 
lid margins, bulbar and tarsal conjunctivas 5 days after ad-
mission. After the surgery, symblepharon rings and thera-
peutic contact lenses were applied in both eyes. Three weeks 
after the operation, the ocular complications disappeared, 
and visual acuity was 20/20 in both eyes without any sym-
blepharon formation.  
DISCUSSION
Various factors have been reported to be associated with 
TEN. Among them, the most frequent causes were drugs 
and infections.1-6 Vaccination for human papillomavirus, 
hepatitis B, smallpox, anthrax, tetanus, mumps, measles, ru-
bella, and influenza has been reported as a rare cause of EM/
SJS/TEN.7-10 To date, there has been no published case of 
TEN related to HFRS vaccination. 
HFRS is a life-threatening disease presented by sudden 
fever, chills, nausea, petechiae, headache, and backache; 
the most serious aspect of the disease is vascular leakage, 
acute shock, and renal failure.11-13 Mortality ranges of HFRS 
have been to be estimated up to 15%.11-13 Approximately 
150,000 to 200,000 patients with HFRS are hospitalized 
each year throughout the world and many of the patients 
are solders and farmers because HFRS is transmitted by rat.12 
In Asia, Hantaan virus and Seoul virus have been identified 
and known as important causative agents for HFRS in Ko-
rea and China.13 
The first Hantaan virus vaccine (Hantavax®) was devel-
oped from suckling mouse brain and inactivated with 0.05% 
formalin.12 The recommended immunization schedule of 
(Fig. 1). Nikolsky sign was positive on erythematous 
zones. The patient had no antecedent medical or surgical 
conditions or medications including NSAID except for two 
doses of HFRS vaccination (Hantavax®; Korea Green 
Cross, Seoul, Korea) at one month interval. The first symp-
tom of bilateral conjunctival injection and tearing devel-
oped one day after second vaccination. And then, other 
symptoms such as swelling of lips, malaise, headache, pha-
ryngeal irritation, and conjunctival itching sense developed. 
However, there were no symptoms such as fever, myalgia, 
nausea, diarrhea, and arthralgia. Skin vesicles and papules 
quickly developed and became widespread involving oral 
mucosa, neck, and upper extremities followed by dissemi-
nation to the trunk and legs. The palms and soles were un-
affected. Laboratory findings including complete blood cell 
count, electrolyte/BUN/Cr analysis, liver function test, 
urine analysis, and tests for autoimmune diseases (anti-nu-
clear antibody, anti-Smith antibody, anti-neutrophil cyto-
plasmic antibody, and smooth muscle antibody) were with-
in normal range. Because the total area of epidermis 
detachment was greater than 30% of total body surface, the 
patient was diagnosed as TEN and high dose systemic cor-
ticosteroid and prophylactic antibiotics with supportive 
treatment were administered. Skin lesions improved slowly 
with these methods.
Ophthalmic examinations revealed visual acuity of 20/40 
and conjunctival injection with medial, inferior, and tempo-
ral conjunctival epithelial defects in both eyes at presenta-
tion (Fig. 2). Topical steroid (PredForte®; Allergan, Irvine, 
CA, USA), antibiotics (Vigamox®; Alcon, Fort Worth, TX, 
USA), and lubricant ointment (Duratears®; Alcon, Fort Worth, 
TX, USA) were applied in both eyes. To minimize ocular 
complication associated with ocular surface inflammation, 
Fig. 1. Photograph of the patient at the first visit. Confluent purpuric and er-
ythematous dusky macules evolving to flaccid blister and epidermal de-
tachment on the whole body predominating the trunk and upper limbs with 
extensive erosions and necroses of the lower lip were shown. 
Fig. 2. Slit-lamp biomicroscopic finding of the right eye at the first visit. 
Conjunctival injection with widespread epithelial defects (area between 
arrows) was revealed. Young Hoon Hwang, et al.
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Research Project from the ROK Defense Ministry. The 
funding sources had no role in study design, data collection 
and analysis, manuscript preparation, or the decision to 
submit the manuscript for publication.
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Hantavax® is a series of two doses one month apart with 
one booster 12 months later.12 From 1990 to 1998, 5,690,000 
doses of Hantavax® were used in Korea (1,162,000 doses to 
soldiers, 20.4%).12 However, little is known about the com-
plications related to Hantavax® vaccination. 
Verification of causes of TEN is difficult. Therefore, tem-
poral relationship and absence of other known causal events 
have been considered as proofs of causal relationship in the 
previous studies.1-10 Considering the temporal relationship 
between the development of TEN and vaccination, the HFRS 
vaccination was the most possible cause in the present case, 
without any other known causes of TEN including infec-
tions and drugs. Bilateral conjunctival injection and tearing 
developed as the first symptom one day after the second 
HFRS vaccination followed by whole body skin eruptions 
in our case, in good accord with the previous studies. Time 
interval between the administration of the vaccine and EM/
SJS/TEN development varied between 1 day and 3 weeks,7-10 
and acute conjunctivitis occurred several hours to 4 days 
before skin eruptions in many cases.5
The mechanism of TEN following HFRS vaccination is 
not clear. It has been hypothesized that the protein compo-
nents of vaccine act like keratinocyte-expressed antigens, 
thus triggering immune reactions.7,12
Ocular involvement of TEN occurs in 50% to 88% of cas-
es and can cause severe complications.1-6 Ocular manage-
ment includes application of lubricant ointment, antibiotics 
to prevent infection, steroids to control inflammation, and 
periodic lysis of symblepharon.14 AMT is known as a re-
cent strategy to suppress inflammation, prevent ulcer for-
mation, and promote healing during the acute stage of TEN, 
thus preventing sight-threatening cicatrical complications.14 
In the present case, ocular complications were recovered 
after AMT with supportive care with eye drops. The AMT 
in acute stage of TEN would be an effective strategy to fa-
cilitate epithelial healing and reduce inflammation as re-
ported previously.14
In conclusion, we experienced the first case of TEN with 
ocular involvement developed after HFRS vaccination. TEN 
may be considered as a possible complication of HFRS vac-
cination. 
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